Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Amortizatization of Intangibles (2020 - 2025)

Avidity Biosciences (RNA) has disclosed Amortizatization of Intangibles for 6 consecutive years, with -$6.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Amortizatization of Intangibles fell 924.64% year-over-year to -$6.8 million, compared with a TTM value of $4.2 million through Dec 2025, up 28.66%, and an annual FY2025 reading of $4.2 million, up 28.66% over the prior year.
  • Amortizatization of Intangibles was -$6.8 million for Q4 2025 at Avidity Biosciences, down from $2.4 million in the prior quarter.
  • Across five years, Amortizatization of Intangibles topped out at $7.8 million in Q2 2025 and bottomed at -$6.8 million in Q4 2025.
  • Average Amortizatization of Intangibles over 5 years is $591350.0, with a median of $801500.0 recorded in 2021.
  • The sharpest move saw Amortizatization of Intangibles surged 8788.89% in 2021, then plummeted 924.64% in 2025.
  • Year by year, Amortizatization of Intangibles stood at $782000.0 in 2021, then plummeted by 285.81% to -$1.5 million in 2022, then surged by 156.71% to $824000.0 in 2023, then changed by 0.0% to $824000.0 in 2024, then tumbled by 924.64% to -$6.8 million in 2025.
  • Business Quant data shows Amortizatization of Intangibles for RNA at -$6.8 million in Q4 2025, $2.4 million in Q3 2025, and $7.8 million in Q2 2025.